Abstract:Background Bladder cancer (BLCA) is a prevalent malignancy affecting the urinary system and is associated with significant morbidity and mortality worldwide. Dysregulation of tumor metabolic pathways is closely linked to the initiation and proliferation of BLCA. Tumor cells exhibit distinct metabolic activities compared to normal cells, and the purine metabolism pathway, responsible for providing essential components for DNA and RNA synthesis, is believed to play a crucial role. However, the precise involvement of Purine Metabolism Genes (PMGs) in the defense mechanism against BLCA remains elusive. Methods The integration of BLCA samples from the TCGA and GEO datasets facilitated the quantitative evaluation of PMGs, offering potential insights into their predictive capabilities. Leveraging the wealth of information encompassing mRNAsi, gene mutations, CNV, TMB, and clinical features within these datasets further enriched the analysis, augmenting its robustness and reliability. Through the utilization of Lasso regression, a prediction model was developed, enabling accurate prognostic assessments within the context of BLCA. Additionally, co-expression analysis shed light on the complex relationship between gene expression patterns and PMGs, unraveling their functional relevance and potential implications in BLCA. Results PMGs exhibited increased expression levels in the high-risk cohort of BLCA patients, even in the absence of other clinical indicators, suggesting their potential as prognostic markers. GSEA revealed enrichment of immunological and tumor-related pathways specifically in the high-risk group. Furthermore, notable differences were observed in immune function and m6a gene expression between the low- and high-risk groups. Several genes, including CLDN6, CES1, SOST, SPRR2A, MYBPH, CGB5, and KRT1, were found to potentially participate in the oncogenic processes underlying BLCA. Additionally, CRTAC1 was identified as potential tumor suppressor genes. Significant discrepancies in immunological function and m6a gene expression were observed between the two risk groups, further highlighting the distinct molecular characteristics associated with different prognostic outcomes. Notably, strong correlations were observed among the prognostic model, CNVs, SNPs, and drug sensitivity profiles. Conclusion PMGs have been implicated in the etiology and progression of bladder cancer (BLCA). Prognostic models corresponding to this malignancy aid in the accurate prediction of patient outcomes. Notably, exploring the potential therapeutic targets within the tumor microenvironment (TME) such as PMGs and immune cell infiltration holds promise for effective BLCA management, albeit necessitating further research. Moreover, the identification of a gene signature associated with purine Metabolism presents a credible and alternative approach for predicting BLCA, signifying a burgeoning avenue for targeted therapeutic investigations in the field of BLCA.

PGK1 can affect the prognosis and development of bladder cancer

The clinical significance and anti-tumor role of PRKG1 in bladder cancer

Systematic Analysis Uncovers Associations of PGK1 with Prognosis and Immunological Characteristics in Breast Cancer

The Predictive Value of PFKFB3 in Bladder Cancer Prognosis

Comprehensive Analysis of Differentially Expressed Genes Associated with PLK1 in Bladder Cancer

PGK1 Promotes NSCLC Progression by Enhancing Aerobic Glycolysis and Activating AKT/ERK Signaling Pathway

Down-Regulated Phosphoglycerate Kinase 1 Expression is Associated with Poor Prognosis in Patients with Gallbladder Cancer

Prognosis and Immunological Characteristics of PGK1 in Lung Adenocarcinoma: A Systematic Analysis

The Oncogenic Role and Regulatory Mechanism of PGK1 in Human Non-Small Cell Lung Cancer

[Influence of Phosphoglycerate Kinase 1 on Metastasis and Invasion of Hepatoma Cells and Prognosis of Liver Cancer].

Glucocorticoid-Inducible Kinase 2 Promotes Bladder Cancer Cell Proliferation, Migration and Invasion by Enhancing Β-Catenin/c-myc Signaling Pathway.

UPP1 enhances bladder cancer progression and gemcitabine resistance through AKT

PGK1-mediated cancer progression and drug resistance

MP51-06 SMYD3 INHIBITION INDUCES PROTECTIVE AUTOPHAGY IN BLADDER CANCER VIA MTOR PATHWAY

Comprehensive Analysis of the Significance of Breast Cancer Gene 1 (BRCA-1) in Bladder Cancer

Upregulation of PAIP1 promotes the gallbladder tumorigenesis through regulating PLK1 level

The prognostic significance of ABCG1 for patients with Bladder cancer

Development and validation of prognostic index based on purine metabolism genes in patients with bladder cancer

Genetic Alteration in Phosphofructokinase Family Promotes Growth of Muscle-Invasive Bladder Cancer

PGK1 Drives Hepatocellular Carcinoma Metastasis by Enhancing Metabolic Process

Pyrimidine metabolism regulator-mediated molecular subtypes display tumor microenvironmental hallmarks and assist precision treatment in bladder cancer